PSA nadir after 125I prostate brachytherapy

Atsunori Yorozu, K. Toya, K. Yoshida, N. Koike, A. Takahashi, S. Saito, T. Nishiyama, Y. Yagi, R. Namitome, A. Ashikari, T. Kono

研究成果: Article


To evaluate the prostate-specific antigen (PSA) kinetics and nadir of PSA failure after permanent 125I prostate brachytherapy. The study included 660 patients with a potential minimum follow-up of 5 years. Patients who met the Phoenix definition of PSA failure were identified. The PSA decreased gradually to less than 0.2ng/mL even after 5 years for many patients. The median PSA nadir was 0.09ng/mL. Neoadjuvant hormone therapy had little effect on PSA nadir. The PSA nadir < = 0.2ng/mL or current nadir < = 0.4ng/mL seemed to be a good marker as a successful treatment.

ジャーナルJapanese Journal of Clinical Radiology
出版物ステータスPublished - 2012 6 10

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

フィンガープリント PSA nadir after <sup>125</sup>I prostate brachytherapy' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Yorozu, A., Toya, K., Yoshida, K., Koike, N., Takahashi, A., Saito, S., Nishiyama, T., Yagi, Y., Namitome, R., Ashikari, A., & Kono, T. (2012). PSA nadir after 125I prostate brachytherapy. Japanese Journal of Clinical Radiology, 57(6), 793-796.